Proguanil Hydrochloride Tablets
Dosage Form | Tablet |
Dose/Strength | Adults 200 mg |
Packaging Size | 100 Tablets |
Packaging Type | Plastic container |
Brand | Yashica |
Storage | Below 25 Degree Celsius |
Exports To: Uganda | Jordan | Uzbekistan | Iraq | Saudi Arabia
Product Details
Company Details
Product Specification
Dosage Form | Tablet |
Dose/Strength | Adults 200 mg |
Packaging Size | 100 Tablets |
Packaging Type | Plastic container |
Brand | Yashica |
Storage | Below 25 Degree Celsius |
Product Description
Uses | It is used for the prevention and treatment of uncomplicated malaria. |
Doses Administration: | It is generally recommended that chemoprophylaxis for travelers should be started about one or two weeks before exposure to malaria, but if this is not possible, it can be started 1 to 2 days prior to travel. The administration should continue throughout exposure and for at least 4 weeks after leaving the malarious area. |
Prevention Of Malaria: | Adults: 200 mg [2 tablets daily] Children: Up to 1 Year: 25 mg [¼ tablet daily] 1 to 4 Years: 50 mg [½ tablet] 5 to 8 Years: 100 mg [1 tablet daily] 9 to 15 Years: 150 mg[1½ tablets daily] To be taken with or after food. For children, may be crushed and mixed with milk, honey or jam. |
Contraindications Warnings: | Should be used with caution in patients with renal impairment; dosage should be reduced accordingly. It is contraindicated in patients with known allergy or any of the excipients used. |
Advertised Effects: | Apart from mild gastric intolerance, diarrhea and some reports of aphthous ulceration there appear to be few adverse effects associated with usual doses of Proguanil hydrochloride. Haematological changes may occur in patients with severe renal impairment. |
Interactions: | Fluvoxamine can virtually abolish the metabolism of Proguanil to its active metabolite cycloguanil via an inhibitory effect on the cytochrome P450 isoenzyme CYP2C19. |
Test | Specification |
Description | White circular flat bevelled edged uncoated tablet having breakline on one side |
Identification (By IR) | Should Comply |
Disintegration Time | NMT 15 minutes |
Related Substances (HPLC) | Should Comply |
Average Wt. | 0.1924 gm |
Dissolution | NLT 70 % |
Assay | 95.0 % to 105.0 % |
Total aerobic microbial Count | NMT 1000 CFU/g |
Total Yeasts and Moulds Count | NMT 100 CFU/g |
E. coli | Should be Absent in 1.0 g |
About the Company
Incorporated in the year 2007, under the visionary Mr. Sanjay Totre, today Yashica Pharmaceuticals has evolved as a pioneer in pharmaceutical drugs worldwide. The quality range of our products includes Active Pharmaceutical Ingredient (API) and Pharmaceutical Intermediates. These are manufactured as per the international standards & meet all regulation of pharmaceutical and chemical industries. With the help of our sound manufacturing facility, we are able to prepare a highly effective range of products. Our professional approach has helped us in maintaining the trust of our clients.
Seller Contact Details
Off. No. 11-12, Shubham Apartment, Syndicate, Kalyan West Thane - 421301, Maharashtra, India
Get Directions